Brief: Gain Therapeutics Announces Dosing Of First Two Subjects In Phase 1 Clinical Trial Of Gt-02287

Gain Therapeutics

04/10/2023 12:08

Oct 4 (Reuters) - Gain Therapeutics Inc  GANX.O :
    * GAIN THERAPEUTICS ANNOUNCES DOSING OF FIRST TWO SUBJECTS
IN
PHASE 1 CLINICAL TRIAL OF GT-02287, A NOVEL GCASE-TARGETING
SMALL MOLECULE THERAPY FOR GBA1 PARKINSON’S DISEASE
    * GAIN THERAPEUTICS ANNOUNCES DOSING OF FIRST TWO SUBJECTS
IN
PHASE 1 CLINICAL TRIAL OF GT-02287, A NOVEL GCASE-TARGETING
SMALL MOLECULE THERAPY FOR GBA1 PARKINSON’S DISEASE
    * GAIN THERAPEUTICS INC - COMPANY EXPECTS TO COMPLETE THIS
TRIAL
IN FIRST HALF OF 2024.
    * GAIN THERAPEUTICS INC - EXPECTS TO COMPLETE TRIAL IN FIRST
HALF
OF 2024
    * GAIN THERAPEUTICS INC - COMPANY EXPECTS TO COMPLETE THIS
TRIAL
IN FIRST HALF OF 2024.

Source text for Eikon:  ID:nGNX9jWwWh 
Further company coverage:  GANX.O 

 ((Reuters.Briefs@thomsonreuters.com))